1032
A. Srikrishna, K. Anebousel6y / Tetrahedron Letters 44 (2003) 1031–1034
described earlier,7 (R)-carvone (7) was converted into
the ketoester 11, via trimethylcarvone 12 and bicy-
clo[2.2.2]octanone 13, employing a regio-, stereo- and
enantiospecific translocation of the isopropenyl side
chain of trimethylcarvone from the C-5 carbon to the
C-2 carbon (as an acetate side chain) strategy. The
keto-ester 11 was transformed into the silyloxy ester 10
employing an intramolecular hydride reduction of the
ketone as the key step.7 The ester 10 was transformed
into the b-ketoester 8 via the aldehyde 14. Thus, lithium
aluminium hydride (LAH) reduction of the ester 10
followed by PCC oxidation of the resultant alcohol
generated the aldehyde 14, [h]2D4 −8.5 (c 4, CHCl3).
Stannous chloride catalysed coupling8 of the aldehyde
14 with ethyl diazoacetate furnished the b-ketoester 8,
[h]2D6 −34 (c 1, CHCl3), in 92% yield. Diazo transfer
reaction with tosyl azide and triethylamine converted
the ketoester 8 into the a-diazo-b-ketoester 15 in 90%
enantiospecific synthesis of a thapsenol. It was antici-
pated that intramolecular cyclopropanation of the dia-
zoketone derived from the b-ketoester 8 would generate
the tricyclic ketone 9, which could be further elaborated
into thapsane 1f. It was contemplated that the ester 10,
which could be obtained from (R)-carvone (7) in opti-
cally active form,7 would serve as an ideal precursor for
the generation of the b-ketoester 8 (Scheme 1).
The synthetic sequence starting from (R)-carvone (7) is
depicted in Schemes 2 and 3. To begin with, as
yield.
A rhodium acetate catalysed stereospecific
intramolecular cyclopropanation9 reaction of the diazo
compound 15 resulted in the formation of the tricyclic
compound† 9, in 45% yield, along with 9% of the
unexpected byproduct† 16. The formation of the
byproduct 16 can be rationalised via CꢀH insertion of
the intermediate rhodium carbenoid through the oxy-
gen of the ketone.10 On the other hand, treatment of
Scheme 1.
† All compounds exhibited spectral data consistent with their structures. Yields refer to isolated and chromatographically pure compounds.
Spectral data for the tricyclic compound 9: [h]D25: −27.86 (c 1.4, CHCl3). IR (neat): wmax 1742, 1722 cm−1 1H NMR (300 MHz, CDCl3+CCl4):
.
l 4.17 (2H, q, J=7.0 Hz), 3.35 (1H, dd, J=11.1 and 4.2 Hz), 2.22 and 1.83 (2H, 2×d, J=18.0 Hz), 1.85–1.50 (4H, m), 1.46 (1H, t of d, J=13.5
and 3.6 Hz), 1.33–1.26 (1H, m), 1.28 (3H, t, J=7.0 Hz), 1.13 (3H, s), 1.11 (3H, s), 0.60 (3H, s), 0.85 (9H, s), 0.05 (6H, s). 13C NMR (75 MHz,
CDCl3+CCl4): l 207.0 (C), 167.9 (C), 76.5 (CH), 61.2 (CH2), 53.5 (C), 49.0 (C), 45.3 (CH2), 44.8 (C), 37.0 (CH2), 33.0 (C), 28.2 (CH3), 27.5
(CH2), 27.0 (CH3), 25.8 (3C, CH3), 18.05 (CH3), 18.0 (C), 17.6 (CH2), 14.0 (CH3), −3.7 (CH3), −5.0 (CH3). For the compound 16: [h]2D5: +31.7
(c 1.2, CHCl3). IR (neat): wmax 1718, 1700, 1663, 891 cm−1 1H NMR (300 MHz, CDCl3+CCl4): l 5.06 (1H, s), 5.00 (1H, s), 4.72 (1H, d, J=1.1
.
Hz, CꢁCH), 4.14 and 4.06 (2H, q of AB q, J=10.6 and 7.0 Hz, OCH2CH3), 2.95 (1H, d, J=16.2 Hz), 2.76 (1H, dd, J=16.2 Hz and 1.6 Hz),
2.15 (1H, t of d, J=14.3 and 4.0 Hz), 1.98 (1H, d of t, J=14.0 and 4.0 Hz), 1.63 (1H, d of t, J=13.2 and 4.0 Hz), 1.36 (1H, t of d, J=14.0
and 4.0 Hz), 1.24 (3H, t, J=7.0 Hz), 1.30 (3H, s), 1.15 (3H, s), 1.11 (3H, s), 0.88 (9H, s), 0.25 (3H, s), 0.10 (3H, s). 13C NMR (75 MHz,
CDCl3+CCl4): l 168.8 (C), 165.2 (C), 157.8 (C), 112.6 (C), 110.1 (CH2), 89.2 (CH, O-CꢁCH), 58.9 (CH2), 50.2 (C), 45.9 (CH2), 35.4 (C), 35.2
(CH2), 31.3 (CH3), 30.1 (2 C, CH3 and CH2), 25.9 (3C, CH3), 25.5 (CH3), 18.1 (C), 14.6 (CH3), −2.9 (CH3), −3.8 (CH3). For the compound 19:
[h]2D4: +20.5 (c 4.0, CHCl3). IR (neat): wmax 1745, 1717, 1653, 883 cm−1. 1H NMR (300 MHz, CDCl3+CCl4): l 4.91 (1H, s), 4.83 (1H, s), 4.22–4.02
(2H, m), 3.63 (1H, br s), 3.41 (1H, dd, J=10.5 and 4.2 Hz), 2.44 and 2.28 (2H, 2×d, J=16.2 Hz), 1.75–1.35 (4H, m), 1.27 (3H, t, J=6.9 Hz),
1.12 (3H, s), 1.00 (3H, s), 0.98 (3H, s), 0.81 (3H, s), 0.88 (9H, s), 0.02 (6H, s). 13C NMR (75 MHz, CDCl3+CCl4): l 173.4 (C), 148.9 (C), 108.5
(CH2), 72.9 (CH), 59.9 (CH2), 54.7 (CH), 54.3 (C), 49.9 (C), 44.0 (CH2), 36.7 (CH2), 36.2 (C), 28.6 (CH3), 27.9 (CH2), 26.1 (3C, CH3), 25.3
(CH3), 18.2 (C), 15.5 (CH3), 14.9 (CH3), 14.5 (CH3), −3.6 (CH3), −4.7 (CH3). For the ethoxy lactone 21: [h]2D5: −40.0 (c 0.6, CHCl3). IR (neat):
wmax 1772 cm−1 1H NMR (300 MHz, CDCl3): l 5.14 (1H, s), 3.87 (1H, q of d, J=9.3 and 6.9 Hz), 3.56 (1H, q of d, J=9.3 and 6.9 Hz), 3.39
.
(1H, dd, J=10.8 and 3.6 Hz), 3.30 (1H, d, J=11.1 Hz), 2.75 (1H, q, J=9.9 Hz), 2.23 (1H, dd, J=12.9 and 9.3 Hz), 1.70–1.20 (5H, m), 1.23
(3H, t, J=6.9 Hz), 1.07 (3H, s), 1.01 (3H, s), 0.97 (3H, s), 0.94 (3H, s), 0.89 (9H, s), 0.06 (3H, s), 0.055 (3H, s). 13C NMR (75 MHz, CDCl3):
l 176.6 (C), 107.9 (CH), 73.0 (CH), 64.9 (CH2), 53.8 (C), 53.3 (C), 51.6 (CH), 44.2 (CH), 40.3 (CH2), 36.9 (CH2), 35.7 (C), 30.3 (CH3), 27.6
(CH2), 25.8 (3C, CH3), 24.5 (CH3), 18.0 (C), 15.8 (CH3), 15.3 (CH3), 14.9 (CH3), −3.7 (CH3), −4.9 (CH3). For the trifluoroacetate 23: mp
100–102°C. [h]2D3: +34.28 (c 1.4, CHCl3). IR (neat): wmax 1776 cm−1 1H NMR (300 MHz, CDCl3): l 4.99 (1H, dd, J=12.2 and 4.4 Hz), 4.44
.
(1H, t, J=9.2 Hz), 3.96 (1H, dd, J=9.6 and 3.9 Hz), 3.30–3.10 (2H, m), 2.00–1.40 (6H, m), 1.17 (3H, s), 1.15 (3H, s), 1.05 (3H, s), 1.04 (3H,
s). 13C NMR (75 MHz, CDCl3): l 176.8 (C), 157.5 (C, q, 2JCꢀF=42 Hz), 114.5 (C, q, 1JCꢀF=284 Hz), 80.3 (CH), 72.7 (CH2), 54.4 (C), 52.6
(C), 50.7 (CH, C-2), 43.8 (CH2), 36.3 (CH2), 35.9 (C), 35.6 (CH), 30.2 (CH3), 24.5 (CH3), 23.6 (CH2), 16.0 (CH3), 15.1 (CH3). For the
(+)-hydroxyacetal 26: mp 110–112°C (lit.:3b 112–114°C). [h]D24: +64.3 (c 0.7, CHCl3) [lit.3b for (−)-26: −67.5 (c 2.4, CHCl3)]. IR (thin film): wmax
3479 cm−1 1H NMR (300 MHz, CDCl3): l 4.79 (1H, s), 3.96 (1H, t, J=7.8 Hz), 3.63 (1H, d, J=7.8 Hz), 3.64–3.58 (1H, m), 3.27 (3H, s),
.
2.85–2.74 (2H, m), 2.25–2.10 (1H, m), 1.80–1.50 (4H, m), 1.35–1.20 (2H, m), 0.96 (6H, s), 0.88 (6H, s). 13C NMR (75 MHz, CDCl3): l 107.3
(CH), 72.5 (CH2), 72.4 (CH), 57.7 (CH), 54.3 (CH3), 53.4 (C), 50.1 (C), 43.4 (CH2), 38.0 (CH), 36.5 (CH2), 35.8 (C), 28.0 (CH3), 27.6 (CH2),
24.6 (CH3), 14.7 (CH3), 13.4 (CH3). For the thapsane 1f: [h]D23: +37.3 (c 1.1, CHCl3) [lit.3b for (−)-1f: −35.7 (c 4.7, CHCl3)]. IR (neat): wmax 3408,
1714, 1650 cm−1 1H NMR (300 MHz, CDCl3): l 5.67 (1H, s), 5.36 (1H, s), 4.99 (1H, dd, J=11.4 and 4.5 Hz), 4.14 (1H, t, J=8.0 Hz), 3.62
.
(1H, d, J=8.0 Hz), 3.05–2.85 (2H, m), 2.21 (1H, br s), 2.17 (3H, s), 1.89 (3H, s), 1.95–1.50 (4H, m) 1.35–1.20 (2H, m), 1.05 (3H, s), 0.99 (3H,
s), 0.94 (3H, s), 0.89 (3H, s). 13C NMR (75 MHz, CDCl3): l 166.6 (C), 156.3 (C), 116.4 (CH), 100.7 (CH), 73.5 (CH), 72.8 (CH2), 58.3 (CH),
52.3 (C), 50.6 (C), 43.5 (CH2), 38.0 (CH), 36.2 (CH2), 35.8 (C), 28.1 (CH3), 27.4 (CH3), 24.6 (CH3), 24.3 (CH2), 20.2 (CH3), 16.0 (CH3), 13.2
(CH3).